ARG1 and neoplasm: It was documented that co-administration of ARG1 vaccine with anti-PD-1 antibodies created a pro-inflammatory microenvironment and changed the M1/M2 macrophage ratio in the tumor, reducing tumor suppressive immunity [152,153].